fashion -WSS

fashion

author：Wikipedia 2025-08-12 09:13:31 - browse：1

a person wearing blue dress conducts a finger prick test on another person in a home setting — coverage from STAT — Adobe

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

A systematic review by the Peterson Health Technology Institute found, though, that digital tools used to manage diabetes with the help of finger-stick blood glucose readings don’t result in clinically meaningful improvements over standard care. As a result, they don’t reduce health care spending — they drive it up.

“Most of the solutions in this category do not deliver clinical benefits that justify their cost,” Caroline Pearson, executive director of the institute, told STAT. Despite finding that some populations may benefit, the report concludes that current evidence doesn’t support broader adoption for most products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Popular nasal decongestant doesn't actually relieve congestion

entertainment

WSS

Donald Trump's relentless attacks on special counsel Jack Smith

How to make the FDA’s new prescription one

Pig kidney works a record two months in donated body

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

How housing is health care on Long Island

The battle over the Brookhaven Landfill on Long Island

Wikipedia

fashion

focus

Virginia high school admissions case could be legal follow

Gene therapy has helped boys walk. Can scientists keep it that way?

Wildfire smoke exposes gaps in outdoor worker protections

Disclosing genetic information: not as worrisome as once feared

How one medical school became remarkably diverse

FDA approves updated Covid vaccines

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The strategy behind pharma's lawsuits over drug pricing reform

Duchenne breakthrough therapy leaves behind pioneering families

Paxlovid study fails to answer questions over benefit for broader groups

hotspot

IRA could hurt research into orphan drugs for rare diseases

In areas with more Black doctors, Black people live longer

White House touts steps to stem shortages of cancer treatments

WATCH: Why do fingernails fall off when they're damaged?

FDA panel endorses Alnylam’s heart drug — after picking it apart

CDC concerned about possible undetected monkeypox spread in U.K.

focus

entertainment

entertainment

focus